Back to Authors

Ross, Melissa

0000-0001-7317-9273

Mayo Clinic

Evidera, Bethesda, MD

Citations 3

Impact of cancer screening results on patient-reported outcomes (PRO) and behavioral intentions.
Patrick, Donald L. , Mulnick, Sarah, Samuelson, Ashley, Cong, Ze, Reid, Robert , Lopatin, Margarita , Fung, Eric T. , Dilaveri, Christina A. , McDonnell, Charles H. , Ross, Melissa , Chung, Karen , Klein, Eric A. , Marinac, Catherine R.

Journal of Clinical Oncology | June 12, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 10608-10608

10.1200/jco.2024.42.16_suppl.10608 Get It

10608 Background: Cancer is one of the most feared diseases. Multi-cancer early detection (MCED) tests have the potential to expand the number of cancers that are detected at earlier stages, which could result in better clinical outcomes. However, behavioral impacts based on MCED test results could affect the utility and value of these tests. Methods: Two independent data sources evaluated the impact of MCED test results on behavioral intentions and perceptions: a survey of the general population and PRO in an MCED clinical trial. A web-based, 30-minute survey of the US general population was used to ascertain attitudes toward a hypothetical MCED test. Eligible respondents were adults aged 40-80 years without a cancer diagnosis in the previous 5 years. The survey assessed the perceived value of negative results (ie, no cancer signal detected [NCSD]) and the projected impact on post-test behaviors. The prospective PATHFINDER study (NCT04241796) of adults aged ≥50 years who underwent MCED cancer screening included PRO assessments. Post-test assessments included: "I am feeling relieved about my test result" from the adapted MICRA and “How likely are you to follow your healthcare provider’s cancer screening recommendations.” The consistency of sentiment after an NCSD MCED result from the online survey and clinical study was assessed. Results: Of the 1073 online survey respondents, 53% were female, 77% White, 14% Black/African American, and 13% Hispanic. Mean age was 58 years. The most common anticipated emotional impacts were relief (84%), happiness (72%), and confidence (69%). Respondents (66-70%) reported they would expect less worry, fear, stress, and anxiety after an NCSD MCED result. The majority (73%) reported they would maintain or improve health behaviors after an NCSD result. NCSD results were projected to lead to an increase in health-related behaviors, including adherence to recommended cancer screening (98%; 68% increase, 30% maintain current level) and regular doctor visits (46%). Of the 6529 PATHFINDER study participants who received NCSD results, 64% were female, 92% White. Mean age was 63 years. 80% of participants (n = 4685/5865) with NCSD felt relief "sometimes" or "often" after their MCED test result. Over 95% of participants (n = 5637/5863) with NCSD indicated they were "likely" or "very likely" to adhere to cancer screening recommendations in the future. Conclusions: Results from a general population survey and a prospective clinical study indicate that an NCSD result may be associated with positive cancer screening intentions and other preventive healthcare behaviors. An NCSD result may also positively impact psychological and emotional health. While these findings suggest that an NCSD result may provide additional value beyond traditional clinical benefits associated with cancer screening, future research is needed to delineate the behavioral impact following MCED screening. Clinical trial information: NCT04241796 .
P936: EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY
Popat, Rakesh , Kleinman, David , Perera, Sue, Gorsh, Boris , Mulnick, Sarah, Alicia, Oneill, Hanna, Maya, Molinari, Alexa , Gelhorn, Heather L. , Popat, Rakesh , Ailawadhi, Sikander , Thomas, Caitlin , Ross, Melissa

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e989881c

10.1097/01.hs9.0000970648.98988.1c Get It

Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment
Popat, Rakesh , Kleinman, David , Perera, Sue , Gorsh, Boris , Mulnick, Sarah, O'Neill, Alicia, Paka, Prani , Hanna, Maya, Molinari, Alexa , Naine, Shivaranjani, Gelhorn, Heather L. , Popat, Rakesh , Ailawadhi, Sikander , Thomas, Caitlin , Ross, Melissa

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7211-7213

10.1182/blood-2022-164795 Get It